Axsome Therapeutics (AXSM) Shares Outstanding (Weighted Average) (2015 - 2026)
Axsome Therapeutics recorded quarterly Shares Outstanding (Weighted Average) of $51.2 million in Q1 2026, up 64528.06% quarter-over-quarter from $79220.0 in Q4 2025, and up 4.76% year-over-year from $48.9 million in Q1 2025.
Axsome Therapeutics' Shares Outstanding (Weighted Average) history runs 12 years deep, the most recent figure standing at $51.2 million for Q1 2026.
- In Q1 2026, Shares Outstanding (Weighted Average) rose 4.76% year-over-year to $51.2 million; the TTM figure through Mar 2026 stood at $51.2 million (up 4.76% YoY), while the FY2025 annual figure was $79220.0, down 99.83% from the prior year.
- Shares Outstanding (Weighted Average) came in at $51.2 million for Q1 2026 at Axsome Therapeutics, up from $79220.0 in the prior quarter.
- In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $51.2 million in Q1 2026 to a low of $50796.0 in Q4 2022.
- A 5-year average of $40.2 million and a median of $45.4 million in 2023 frame the typical range for Shares Outstanding (Weighted Average).
- Across the five-year window, Shares Outstanding (Weighted Average) surged 89326.75% in 2023 and slumped 99.83% in 2025, its largest moves.
- Axsome Therapeutics' Shares Outstanding (Weighted Average) stood at $50796.0 in 2022, then soared by 89326.75% to $45.4 million in 2023, then climbed by 5.48% to $47.9 million in 2024, then plunged by 99.83% to $79220.0 in 2025, then surged by 64528.06% to $51.2 million in 2026.
- According to Business Quant data, Shares Outstanding (Weighted Average) over the past three periods registered $51.2 million, $79220.0, and $49.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares (Weighted Avg.) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 177,333.76 Bn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 185,491.37 Bn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 100.00 Bn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 55.66 Bn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 118.76 Bn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 254.10 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 16.04 Bn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 104.00 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 132.89 Mn |
| 10 | Axsome Therapeutics | 11.82 Bn | 11.51 Bn | 176.48 Mn | 51.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 51.20 Mn |
| Dec 31, 2025 | 79,220.00 |
| Sep 30, 2025 | 49.45 Mn |
| Jun 30, 2025 | 49.16 Mn |
| Mar 31, 2025 | 48.87 Mn |
| Dec 31, 2024 | 47.91 Mn |
| Sep 30, 2024 | 48.14 Mn |
| Jun 30, 2024 | 47.48 Mn |
| Mar 31, 2024 | 47.39 Mn |
| Dec 31, 2023 | 45.43 Mn |
| Sep 30, 2023 | 44.78 Mn |
| Jun 30, 2023 | 43.60 Mn |
| Mar 31, 2023 | 43.52 Mn |
| Dec 31, 2022 | 50,796.00 |
| Sep 30, 2022 | 39.72 Mn |
| Jun 30, 2022 | 38.70 Mn |
| Mar 31, 2022 | 38.32 Mn |
| Dec 31, 2021 | 15,541.00 |
| Sep 30, 2021 | 37.68 Mn |
| Jun 30, 2021 | 37.60 Mn |
| Mar 31, 2021 | 37.43 Mn |
| Dec 31, 2020 | 15,541.00 |
| Sep 30, 2020 | 37.16 Mn |
| Jun 30, 2020 | 37.08 Mn |
| Mar 31, 2020 | 37.06 Mn |
| Dec 31, 2019 | 69,656.00 |
| Sep 30, 2019 | 33.77 Mn |
| Jun 30, 2019 | 33.43 Mn |
| Mar 31, 2019 | 33.05 Mn |
| Dec 31, 2018 | 123,037.00 |
| Sep 30, 2018 | 26.33 Mn |
| Jun 30, 2018 | 25.79 Mn |
| Mar 31, 2018 | 25.50 Mn |
| Dec 31, 2017 | 2.10 Mn |
| Sep 30, 2017 | 23.63 Mn |
| Jun 30, 2017 | 23.60 Mn |
| Mar 31, 2017 | 19.54 Mn |
| Dec 31, 2016 | 337,746.00 |
| Sep 30, 2016 | 19.15 Mn |
| Jun 30, 2016 | 19.15 Mn |
| Mar 31, 2016 | 19.15 Mn |
| Dec 31, 2015 | 272,518.00 |
| Sep 30, 2015 | 11.11 Mn |
| Jun 30, 2015 | 11.11 Mn |
| Mar 31, 2015 | 11.11 Mn |